FAQs on EGFR-Mutated NSCLC
Managing EGFR-Mutated Non-Small-Cell Lung Cancer in Today’s Clinic: Expert Answers to Frequently Asked Questions

Released: September 28, 2022

Expiration: September 27, 2023

Ryan D. Gentzler
Ryan D. Gentzler, MD, MS
Jonathan Riess
Jonathan Riess, MD, MS

Activity

Progress
1
Course Completed

In this episode, Ryan D. Gentzler, MD, MS, and Jonathan Riess, MD, MS, answer audience questions on managing EGFR-mutated non-small-cell lung cancer (NSCLC) from a live meeting series. The episode includes expert insights on:

  • Identifying patients who may benefit the most from adjuvant osimertinib
  • Testing for EGFR mutations in early-stage NSCLC
  • Critical importance of getting molecular test results before starting immunotherapy
  • Monitoring cardiac toxicity in patients receiving osimertinib
  • Key ongoing trials in EGFR-mutated NSCLC for patients with newly diagnosed disease and following progression on osimertinib